Arcus Biosciences Profitability Analysis
| RCUS Stock | USD 24.80 0.02 0.08% |
Net Loss | First Reported 2016-12-31 | Previous Quarter -98 million | Current Value -128 million | Quarterly Volatility 65.78 million |
Macro event markers
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 77.00% | 86.00% |
|
|
Profitability metrics for Arcus Biosciences reflect a business that is consuming more capital than it generates, with deep negative margins across the income statement. Gross margin of 77.0% narrows sharply to a net margin of -150.0%, indicating that overhead, financing, or non-operating costs consume a large share of gross profit. Return on equity of -59.0% and return on assets of -33.0% confirm that capital is not generating positive returns at current operating levels. Figures reflect Arcus Biosciences' last reported annual data.
Arcus |
Revenue by Product Segment
Arcus Biosciences' reported product mix includes 2 disclosed revenue streams. The reported segment mix is led by License And Development Services at 12 million, followed by Other Collaboration Revenue at 5 million. Arcus Biosciences' disclosed segment data helps frame product mix, even when the reported segment totals do not map cleanly to consolidated revenue.
Arcus Biosciences has a market cap of 3.27 billion, an operating margin of -3.45% on a trailing twelve-month basis, compared to -1.64% in the last reported annual period, current ratio of 6.22. How positions are weighted depends on the construction approach applied. Broader economic conditions can influence Arcus Biosciences's company valuation - related indicators include signals in main economic indicators.For background on Arcus Stock, review our How to Trade Arcus Stock resource. This guide walks you through the practical steps for investing in Arcus Biosciences. It is designed for both experienced investors and those new to trading Arcus Stock.Earnings estimate revisions for Arcus Biosciences serve as a real-time gauge of how the fundamental outlook is shifting. Operating margin of -164.0% and net margin of -150.0% outline the cost layers between Arcus Biosciences' revenue and earnings. At Arcus Biosciences, the relationship between EPS, operating leverage, and reinvestment rate shapes the earnings picture. EPS TTM reflects trailing reported results and does not imply future performance. Consensus EPS estimates for Arcus Biosciences typically reference EPS before non-recurring items. The figures can incorporate expenses tied to employee stock options.
Macro event markers
Revenue Breakdown by Earning Segment for Arcus Biosciences Overview
This chart illustrates Arcus Biosciences' revenue composition by product line based on the latest available data. The smallest reported segment is Other Collaboration Revenue at 5 million.
Cash per share of Arcus Biosciences indicates the liquid resources available alongside reported earnings. The revision trajectory — whether estimates are rising, flat, or falling — often carries more signal than the absolute level.
Earnings Share -3.17 | Revenue Per Share | Quarterly Revenue Growth 26.9% | Return On Assets | Return On Equity |
For Arcus Biosciences, market value and book value represent two distinct lenses on the same underlying business. Trading price represents the transaction level agreed by market participants.
Arcus Biosciences' estimated value and market price are complementary but separate measures of worth. Arcus Biosciences' trading price represents the transaction level agreed by market participants.
Arcus Biosciences Return On Asset TTM vs. Return On Equity TTM Fundamental Analysis
ROE stood at -0.59 as of December 31, 2025. Related reported metric: Return On Asset TTM at -33.00% as of December 31, 2025.
Arcus Return On Asset TTM vs. Return On Equity TTM
Arcus Biosciences's Return on Equity of -59.0% is negative, indicating the company is generating losses relative to shareholders' equity. A negative ROE means equity capital is being eroded rather than producing returns, which typically signals a period of restructuring, heavy investment, or persistent operational weakness.
Arcus Biosciences |
| = | -0.59 |
Arcus Biosciences's Return on Assets of -33.0% indicates the company is not generating sufficient income to justify its asset base. Negative asset returns typically point to operational losses or a business model requiring substantial asset investment relative to current earnings capacity.
Arcus Biosciences |
| = | -0.33 |
Arcus Biosciences's negative ROE paired with its ROA performance indicates losses are flowing directly to equity holders. Evaluating the capital structure becomes critical when returns are negative, as leverage magnifies losses in the same way it amplifies gains.
Arcus Return On Asset TTM Comparison
Arcus Biosciences is currently under evaluation in return on asset ttm relative to competitors.
Estimated Months Earnings per Share
This chart shows the estimate series used for upcoming reporting periods.
Detailed Analysis of Earnings Estimates
Latest Earning Estimates and Surprises
The table below lists reported EPS, estimated EPS, and the reported surprise for each available quarter.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2026-05-12 | 2026-03-31 | -1.1 | -1.02 | 0.08 | 7 | ||
2026-02-25 | 2025-12-31 | -1.1 | -0.89 | 0.21 | 19 | ||
2025-10-28 | 2025-09-30 | -1.28 | -1.27 | 0.01 | 0 | ||
null | null | null | null | null | 0 | ||
2025-05-06 | 2025-03-31 | -0.93 | -1.14 | -0.21 | 22 | ||
2025-02-19 | 2024-12-31 | -1.2031 | -1.03 | 0.1731 | 14 | ||
2024-11-06 | 2024-09-30 | -1.06 | -1.0 | 0.06 | 5 |